Proactive Investors - Run By Investors For Investors

Jazz Pharmaceuticals jumps as it agrees patent settlement with Hikma on narcolepsy treatment

Jazz will grant Hikma and its wholly-owned subsidiary West-Ward Pharmaceuticals Corp the right to sell an authorised generic version of Xyrem in the US from the beginning of January 2023
Daytime sleepiness
Sales of Xyrem were reported at around US$D1.11bn in 2016, according to Jazz's annual report

Nasdaq–listed, Dublin-based biopharmaceuticals firm Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) saw its shares jump by over 6% in pre-market trading today after it agreed a settlement with London-listed  Hikma Pharmaceuticals PLC (LON:HIK) which resolves a patent litigation with regards to Jazz's narcolepsy treatment, Xyrem.

Under the settlement, Jazz will grant Hikma and its wholly-owned subsidiary West-Ward Pharmaceuticals Corp the right to sell an authorised generic version of Xyrem in the US from the beginning of January 2023.

Hikma will pay a royalty on net sales of the excessive sleepiness treatment, but will initially retail a "meaningful percentage" of net sales, the UK firm said in a statement.

The FTSE 100-listed group will also pay for the supply of the generic drug, and reimburse Jazz with a portion of the service costs.

Sales of Xyrem were reported at around US$D1.11bn in 2016, according to Jazz's annual report.

The initial term of the agreement is six months, and Hikma will have the option to extend this term for a total of five years.

Jazz has also agreed to grant Hikma a licence to market generic sodium oxybate, the active ingredient in Xyrem at the end of the term.

In pre-market trading in New York, Jazz shares were 6.1% higher at US$149.20, while in London, Hikma shares were 16p lower at 1,916p.

View full JAZZ profile View Profile

Jazz Pharmaceuticals PLC Timeline

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use